Opus Genetics (IRD) Earnings Analysis

Opus Genetics (IRD) next reports earnings on 2026-08-12, consensus EPS -0.15 USD. Last quarter (2026-05-21) it missed with EPS -0.19 USD vs -0.16 USD est (-18.8%). It has beaten estimates in 2/4 recent quarters (50%). Trailing P/E -2.33.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does IRD next report earnings?

Next earnings date2026-08-12
Consensus EPS estimate-0.15 USD
Revenue estimate0.00B

IRD earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-21-0.19 USD-0.16 USD-18.8%Miss
2025-08-13-0.12 USD-0.25 USD+52%Beat
2025-05-15-0.32 USD-0.34 USD+5.9%Beat
2025-03-31-1.27 USD-0.34 USD-273.5%Miss

Beat rate: 2/4 (50%) over reported quarters with consensus data.

IRD valuation and analyst view

Trailing P/E-2.33
Trailing EPS-0.12306 USD
Price / book-57.82
Dividend yield0.00%
Market cap0.25B
Analyst consensusBuy (7 buy / 0 hold / 0 sell)
Avg price target9.33 USD

Related research pages

Frequently asked questions

When is Opus Genetics (IRD)'s next earnings date?

Opus Genetics is next scheduled to report on 2026-08-12, with a consensus EPS estimate of -0.15 USD and revenue estimate of 0.00B.

Did IRD beat earnings last quarter?

In its 2026-05-21 report, IRD posted EPS of -0.19 USD versus a -0.16 USD estimate — a miss of 18.8%.

What is IRD's earnings track record?

Over the last 4 reported quarters with consensus data, IRD beat estimates 2 times (50%).

What is IRD's current P/E ratio and EPS?

IRD trades at a trailing P/E of -2.33 on trailing EPS of -0.12306403058384913 USD.

What do analysts rate IRD?

Analyst consensus is "Buy" across 7 ratings (0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 9.33 USD.